

Please note our distinction between *precision health (PH)* and *precision medicine (PM)*. Be sure that your proposal falls within the scope of this definition **PH** and **NOT PM** in order to be considered for this seed/dream team funding opportunity. Namely, therapies, drug screening, therapeutic efficacy, and existing disease states and/or conditions are outside the scope of **PH**. Think about approaches to keep people as healthy as possible, rather than interventions and treatments of already existing diseases.

The following examples should aid in clarifying the differences:

PH: Using –omics/biomarkers for prediction of future disease occurrence in healthy individuals or populations.

PM: Using –omics/biomarkers for prediction, development, or validation of treatments/therapies and drug sensitivities.

PH: Wearable/nanotechnology for early diagnostics of disease or to better understand the transition from health to disease.

PM: Wearable/nanotechnology to predict recovery from condition/disease or monitor progression of prevalent condition/disease.

PH: Strategies for early disease detection

PM: Strategies for monitoring for disease recurrence in someone who has already previously been treated for the disease

PH: Predicting risk of a given disease based on multiple factors

PM: Predicting response to therapy or monitoring response to therapy

There of course will be numerous possibilities, but overall proposals should involve an approach that is intended to be applied to a healthy individual or population(s) (prior to the occurrence of disease and of a non-therapeutic nature). Remember to contact Dr. Ryan Spitler if you are not sure if your research might fit into the PHIND Center goals.